Used in targeted cancer therapies, particularly in tumors with FGFR1 overexpression such as breast cancer, lung cancer, and certain hematological malignancies. This antibody modulates FGFR1 signaling to inhibit tumor growth and angiogenesis. It serves as a research tool for validating FGFR1 as a therapeutic target and supports the development of antibody-drug conjugates or bispecific antibodies. Also utilized in diagnostic assays to detect FGFR1 expression levels in patient samples for personalized medicine approaches.